By Eugene L. Heyden, RN “Studies have shown that opioids have immunomodulatory activity, including modulation of the inflammatory response and healing and repair of tissues. Short-term blockade of opioid receptors leads to increased endogenous levels of opioids, which is the basis for naltrexone use in CD [Crohn’s disease].”  ~ Kais, 2013 “Signaling through opioid…